Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389829 | 0.85 | MTNR1A (0.48) | MTNR1AMTNR1BHDAC11HDAC8HDAC6 | |
| SCHEMBL7554460 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BDRD2DRD4HDAC11 | |
| SCHEMBL7554464 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BDRD2DRD4HDAC11 | |
| SCHEMBL27883632 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BDRD2DRD4BRD4 | |
| SCHEMBL11395137 | 0.80 | CHRM2 (0.41) | MTNR1AMTNR1BDRD2DRD4GAA | |
| SCHEMBL6102422 | 0.80 | CHRM2 (0.41) | MTNR1AMTNR1BDRD2DRD4GAA | |
| SCHEMBL6101026 | 0.80 | CHRM2 (0.41) | MTNR1AMTNR1BDRD2DRD4GAA | |
| SCHEMBL11065983 | 0.78 | EHMT2 (0.49) | GAAMEN1KMT2ALMNA | |
| SCHEMBL27278853 | 0.78 | EHMT2 (0.49) | GAAMEN1KMT2ALMNA | |
| SCHEMBL27818626 | 0.78 | MTNR1A (0.45) | MTNR1AMTNR1BHDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | NEUROGEN CORPORATION. | 2002-09-12 | — | — | US | disclosed |
| US-6355644-B1 | NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | GABRP, GABBR1, GABARAP | MTNR1A 311/4885MTNR1B 255/4885DRD2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.